Enzybiotics, A New Class of Enzyme Antimicrobials Targeted against Multidrug-Resistant Superbugs

Asit Kumar Chakraborty
Additional contact information
Asit Kumar Chakraborty: Department of Biochemistry and Biotechnology, Vidyasagar University, India

Novel Approaches in Drug Designing & Development, 2017, vol. 2, issue 4, 71-74

Abstract: Gut microbiota with 2X1012 bacterial populations is essential for synthesis of vitamins, coenzymes and many other biomolecules in human and animal. But high dose of antibiotics destructed (since 1928) such bacteria in the alimentary tract posing a threat to extinct of human life. As a result signalling from human and bacteria orchestrated to build a defence to protect symbiotic relations saving both life forms. Bacteria synthesized hundreds of new genes (MDR Genes) to destroy antibiotics in different modes of actions. G-20 leaders and scientists have vowed a strong action plans (as assembled recently in Germany) to abolish the horror of superbugs which are claiming millions of death worldwide. Enzymes as therapeutic antibiotics has taken as emerging new antimicrobials derived from bacteriophages as well as bacteria like Staphylococcus sp., Streptococcus sp. and Histeria monocytogenes. Simply, autolysins, lysozymes, lysins and bacteriocins are great enzybiotics. Genetically modified enzybiotic (GMEnzy) has now a new field of enzyme antibiotic production using molecular biology and genetic engineering principles to overcome the antibiotic resistance. GMEnzy database has built for researchers and is available at http://biotechlab.fudan.edu.cn/database/gmenzy/.

Keywords: juniper publishers; drug designing pdf; drug designing articles; drug designing abstract; drug designing journal; modern approaches in drug designing journal; drug designing & intellectual properties international journal; peer reviewed open access journals; high impact journals; juniper publishers review (search for similar items in EconPapers)
Date: 2017
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/napdd/pdf/NAPDD.MS.ID.555592.pdf (application/pdf)
https://juniperpublishers.com/napdd/NAPDD.MS.ID.555592.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jnapdd:v:2:y:2017:i:4:p:71-74

DOI: 10.19080/NAPDD.2017.02.555592

Access Statistics for this article

Novel Approaches in Drug Designing & Development is currently edited by Sophia Mathis

More articles in Novel Approaches in Drug Designing & Development from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().